Skip to main content
Evidence Snapshot

CDK9/cyclin T1

CHEMBL2111389 PROTEIN COMPLEX Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:31:05Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2111389
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats CDK9/cyclin T1 as ChEMBL target CHEMBL2111389, mapped to UniProt O60563. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
CDK9/cyclin T1
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2111389
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O60563
Cyclin-T1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why CDK9/cyclin T1 matters

As of 2026-09-13

CDK9/cyclin T1 is reviewed as Cyclin-T1 (UniProt O60563); the current evidence base includes 5 approved drugs, 3966 compounds, and 548 assays, with lead potency reaching pChEMBL 10.1.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 3966 compounds, and 548 assays for this target. The dominant activity type is IC50. CHEMBL4462530 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL4462530 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 10.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why CDK9/cyclin T1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O60563, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3966
Total Compounds
548
Total Assays
5
Approved Drugs
IC50: 3269.0, KI: 245.0, KD: 16.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4462530
 10.1 Kd Clinical
No preferred name
CHEMBL4754081
 9.9 Kd —
No preferred name
CHEMBL4754399
 9.5 Kd —
No preferred name
CHEMBL4217448
 9.4 IC50 —
No preferred name
CHEMBL3932121
 9.4 Ki —

Approved Drugs

Structure Compound First Approval
ABEMACICLIB
CHEMBL3301610
 2017
RIBOCICLIB
CHEMBL3545110
 2017
PALBOCICLIB
CHEMBL189963
 2015
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:31:05Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2111389